Cancer Maintenance After NED: A Multi-Axis Metabolic & Precision Survivorship Framework

2026 Evidence Update | NED • Minimal Residual Disease • Cancer Recurrence • Metabolic Health • Survivorship • Repurposed Therapies

Important: This article is an evidence-informed framework for discussing long-term cancer survivorship and recurrence-risk reduction with a qualified oncology team. It is not a universal cancer-maintenance protocol and should not be used to self-prescribe prescription medicines, veterinary drugs, supplements, fasting regimens, or other off-label therapies.

Key Takeaway

Achieving NED (No Evidence of Disease) is an important milestone, but it is not synonymous with a guarantee that cancer can never return.

The modern survivorship question is therefore broader than simply:

"Is there cancer on the scan?"

A better question is:

"How can we systematically reduce recurrence risk, detect molecular or clinical relapse as early as possible, preserve physical function, and maintain long-term metabolic and immune health?"

This article combines two complementary ideas: conventional cancer surveillance and survivorship care, together with a hypothesis-driven multi-axis metabolic approach that considers glucose/insulin regulation, inflammation, body composition, mitochondrial health, immune function, circadian biology and the tumor microenvironment.

The crucial distinction is that some elements of this strategy have strong survivorship evidence, while others remain experimental.

Contents

1. What Does NED Really Mean?
2. What Is Cancer Maintenance Therapy?
3. Risk Stratification Comes First
4. Surveillance and Early Detection
5. The Emerging Role of ctDNA
6. The Multi-Axis Metabolic Framework
7. Diet and Metabolic Health
8. Exercise and Muscle Preservation
9. Sleep and Circadian Health
10. Nutraceuticals: What We Know and Don't Know
11. Repurposed Drugs: Promise Versus Proof
12. Modified Citrus Pectin and Galectin-3
13. Should Metabolic Therapy Be Cycled?
14. A Practical Risk-Stratified Framework
15. Questions to Ask Your Oncology Team
16. Evidence Hierarchy
17. Conclusion

1. What Does NED Really Mean?

NED means that currently available clinical tests do not show detectable cancer.

It does not necessarily mean that every malignant cell has been eliminated. Depending on the cancer type, stage and biology, microscopic residual disease may remain below the detection threshold of conventional imaging or laboratory testing.

This is one reason recurrence can occur after an apparently successful treatment.

However, it is equally important not to overstate this concept. NED should not be interpreted as proof that a patient has hidden cancer cells. For many patients, NED represents durable remission or cure.

The appropriate approach therefore combines hope, surveillance and risk management rather than assuming that recurrence is inevitable.

2. What Is Cancer Maintenance Therapy?

Maintenance therapy has different meanings in different cancers.

In conventional oncology, maintenance treatment may refer to an evidence-based systemic treatment deliberately continued after initial therapy to prolong disease control. Examples include selected hormonal therapies, targeted therapies, immunotherapies or other treatments depending on the cancer.

That is different from the broader concept of metabolic maintenance discussed here.

Metabolic maintenance refers to long-term strategies intended to:

• maintain healthy glucose and insulin regulation;
• preserve muscle and physical function;
• reduce excess adiposity;
• support cardiovascular and metabolic health;
• reduce chronic inflammation;
• support immune function;
• maintain healthy sleep and circadian rhythms;
• avoid tobacco and minimize alcohol exposure;
• and maintain appropriate cancer surveillance.

Some researchers and clinicians have also proposed adding repurposed drugs and nutraceuticals to this framework. These approaches remain substantially less established and should be separated from evidence-based survivorship care.

3. Risk Stratification Comes First

Not every NED patient has the same recurrence risk.

A rational maintenance strategy should therefore begin with a structured assessment of:

• original cancer type;
• stage at diagnosis;
• tumor grade;
• lymph-node involvement;
• metastatic history;
• residual disease status;
• molecular and genomic characteristics;
• response to treatment;
• prior recurrence;
• tumor-specific biomarkers;
• ctDNA/MRD results when clinically appropriate;
• current metabolic health;
• body composition and muscle mass;
• treatment toxicity;
• and overall functional status.

A patient with a low-risk tumor that has remained disease-free for many years is fundamentally different from a patient who previously had metastatic disease, aggressive biology or repeated recurrence.

The intensity of any long-term strategy should therefore be proportional to the patient's actual risk.

4. Surveillance and Early Detection Remain Essential

Metabolic health should never become a substitute for appropriate oncology surveillance.

Depending on the cancer, surveillance may include:

• physical examination;
• tumor-specific blood tests;
• imaging;
• endoscopic surveillance;
• mammography or other cancer-specific screening;
• PSA monitoring;
• molecular testing;
• ctDNA testing in selected settings;
• and assessment of symptoms and functional status.

The precise schedule should be determined by the cancer type, stage, treatment history and recurrence risk.

One of the most important principles is to evaluate trends rather than isolated numbers.

5. The Emerging Role of ctDNA

Circulating tumor DNA (ctDNA) is one of the most promising technologies for detecting minimal residual disease in selected solid tumors.

ctDNA can sometimes detect molecular evidence of residual disease before recurrence becomes visible on conventional imaging. This creates the possibility of identifying patients at particularly high risk of recurrence after apparently successful treatment.

But there is a critical distinction:

ctDNA is a risk marker, not automatically a treatment trigger.

A positive ctDNA result does not by itself establish where the disease is located, what treatment should be given, or that treatment based solely on ctDNA improves survival across all cancers.

Similarly, a negative ctDNA result does not prove that microscopic disease is absent.

Therefore, ctDNA is best understood as part of a broader precision surveillance strategy rather than a replacement for clinical assessment.

6. The Multi-Axis Metabolic Framework

The metabolic approach proposes that recurrence biology should not be viewed exclusively through the lens of tumor-cell proliferation.

It considers several interacting systems:

• Glucose and insulin: metabolic dysfunction and hyperinsulinemia may influence growth signaling in some cancers.
• Inflammation: chronic inflammatory signaling can influence the tumor microenvironment.
• Mitochondrial biology: cancer cells demonstrate substantial metabolic plasticity.
• Immune surveillance: immune function is central to controlling residual malignant cells.
• Angiogenesis: vascular signaling influences tumor growth and dissemination.
• Stress signaling: neuroendocrine and adrenergic pathways may influence cancer biology.
• Microbiome: intestinal microbial composition can affect metabolism and immune function.
• Circadian biology: sleep and circadian disruption affect metabolic and immune regulation.
• Body composition: preservation of muscle is particularly important during and after cancer treatment.

This does not mean that correcting these systems can independently "starve" cancer or guarantee prevention of recurrence. Rather, it provides a framework for improving overall physiologic resilience while conventional cancer-specific surveillance continues.

7. Diet and Metabolic Health

Diet should be considered a long-term health intervention rather than a short-term "anticancer diet."

A practical survivorship pattern emphasizes:

• vegetables and other minimally processed plant foods;
• fruit in appropriate portions;
• whole grains and legumes when tolerated;
• adequate protein;
• fish, poultry and other nutrient-dense protein sources;
• high-fiber foods;
• healthy unsaturated fats;
• minimizing sugar-sweetened beverages;
• limiting ultra-processed foods;
• limiting processed meat;
• avoiding smoking;
• and minimizing or avoiding alcohol.

For patients with insulin resistance, obesity, diabetes or metabolic syndrome, individualized nutritional intervention may be particularly valuable.

Importantly, aggressive calorie restriction is not appropriate for every cancer survivor. Patients who are underweight, losing weight unintentionally, sarcopenic or recovering from intensive therapy may need more calories and protein rather than fewer.

8. Exercise and Muscle Preservation

Exercise is among the strongest components of the survivorship framework.

Physical activity can improve:

• cardiorespiratory fitness;
• insulin sensitivity;
• body composition;
• muscle mass;
• physical function;
• fatigue;
• sleep;
• mood;
• cardiovascular health;
• and quality of life.

Current cancer-survivorship guidance generally encourages progression toward approximately 150–300 minutes of moderate activity per week, or 75–150 minutes of vigorous activity, combined with muscle-strengthening exercise at least two days per week when medically appropriate.

For many cancer survivors, maintaining muscle may be more important than achieving an arbitrarily low body weight.

A practical program can combine:

• daily walking;
• aerobic exercise;
• resistance training;
• mobility work;
• balance training where appropriate;
• and gradual progression based on fitness and treatment history.

9. Sleep and Circadian Health

Sleep is frequently overlooked in cancer survivorship.

A long-term program should prioritize:

• consistent sleep and wake times;
• adequate sleep duration;
• morning daylight exposure;
• regular daytime physical activity;
• minimizing excessive nighttime light exposure;
• treating sleep apnea when present;
• and addressing chronic psychological stress.

Melatonin has attracted considerable interest in cancer research, but laboratory and mechanistic evidence should not be confused with proof that melatonin supplementation prevents cancer recurrence.

10. Nutraceuticals: What We Know and Don't Know

The original maintenance article listed a large number of supplements including vitamin D, omega-3 fatty acids, magnesium, curcumin, EGCG, sulforaphane, quercetin, berberine, probiotics and melatonin.

These compounds have varying degrees of biological plausibility and clinical evidence.

They should not all be placed into the same evidence category.

A more appropriate classification

Category A — Correct documented deficiency or nutritional need

• Vitamin D when deficiency is documented.
• Iron, B12, folate or other nutrients when deficiency is demonstrated.
• Protein and other nutritional support when clinically indicated.

Category B — General health / survivorship support

• adequate dietary fiber;
• omega-3-rich foods;
• nutrient-dense whole foods;
• adequate magnesium and other micronutrients through diet.

Category C — Mechanistically interesting but not proven to prevent recurrence

• EGCG;
• curcumin;
• sulforaphane;
• quercetin;
• berberine;
• pterostilbene;
• melatonin;
• modified citrus pectin.

The important editorial correction is therefore:

Biological plausibility is not the same thing as demonstrated recurrence-prevention benefit.

11. Repurposed Drugs: Promise Versus Proof

Repurposed drugs are attractive in oncology because many have established pharmacology, known human safety information for their approved indications and relatively low acquisition costs.

However, cancer treatment requires evidence of benefit at clinically relevant doses and in appropriately selected patients.

Ivermectin

Ivermectin has demonstrated anticancer activity in multiple laboratory and animal models involving pathways such as Wnt/β-catenin, Akt/mTOR and other signaling systems.

However, a 2025 clinical review concluded that human evidence remains limited and that large randomized trials demonstrating anticancer benefit are lacking.

A 2026 real-world study of ivermectin and mebendazole adds observational patient-reported data, but this type of evidence cannot establish causality or prove that the drugs prevent recurrence.

Editorial classification: Experimental / hypothesis-generating.

Mebendazole

Mebendazole has a substantial preclinical literature and has entered early clinical testing.

A 2025 phase I study in children with refractory or recurrent brain tumors found that mebendazole was tolerable at the investigated dose levels, but the study showed limited evidence of single-agent efficacy.

Editorial classification: Early clinical / investigational.

Fenbendazole

Fenbendazole remains particularly controversial because most of the evidence consists of laboratory research, animal work and anecdotal or case-based reports.

Importantly, a 2025 case series of three patients was subsequently accompanied by a 2026 retraction statement. It should therefore not be cited as reliable clinical evidence of efficacy.

Editorial classification: Preclinical / insufficient clinical evidence.

Metformin

Metformin is particularly interesting because of its established effects on glucose metabolism and AMPK-related signaling and its extensive clinical safety experience in diabetes.

However, observational associations do not automatically demonstrate an anticancer effect.

Randomized trials are essential to determine whether metformin improves cancer outcomes in specific populations. For example, the 2025 Metformin Active Surveillance Trial investigated whether metformin could delay progression in men with low-risk prostate cancer rather than assuming benefit from mechanism alone.

Editorial classification: Cancer-specific evidence required; not a universal NED therapy.

Statins and beta-blockers

Statins and beta-blockers have generated interesting observational and mechanistic signals in cancer research.

But an association between medication exposure and improved outcomes is not sufficient to establish that these drugs should be prescribed specifically to prevent recurrence.

If a patient already has an accepted cardiovascular or metabolic indication, the cancer-related evidence can become part of the broader risk-benefit discussion with the treating physician.

12. Modified Citrus Pectin and Galectin-3

Modified citrus pectin (MCP) is another component of the proposed metabolic-maintenance model.

Its biological rationale centers partly on galectin-3, a protein involved in cell adhesion, inflammation, fibrosis, angiogenesis and tumor-microenvironment biology.

This makes galectin-3 an interesting research target, particularly in the context of metastatic biology.

However, the existence of a plausible molecular target does not establish that MCP prevents recurrence in NED patients.

The appropriate description is therefore:

MCP is a biologically interesting adjunctive strategy under investigation, not a proven recurrence-prevention treatment.

Any use should also consider medication timing, gastrointestinal tolerance and potential interactions with oral medications.

13. Should Metabolic Therapy Be Cycled?

The "rotational therapy" concept is based on evolutionary reasoning.

In theory, continuously applying the same selective pressure could favor resistant or metabolically adaptable cancer-cell populations, whereas changing pressures might make adaptation more difficult.

This is an important hypothesis in cancer biology.

But the leap from evolutionary theory to a specific patient schedule is substantial.

There is currently insufficient evidence to establish a universal schedule such as:

• specific weeks on and off;
• monthly drug rotations;
• specific combinations of repurposed drugs;
• or a standardized "metabolic trap" protocol for all NED patients.

Therefore, rotation should be described as an investigational treatment concept, not a validated maintenance prescription.

14. A Practical Risk-Stratified Framework

Tier 1 — Every NED patient

• Follow cancer-specific surveillance.
• Know the original pathology and molecular profile.
• Maintain or rebuild muscle mass.
• Exercise regularly.
• Adopt a nutrient-dense, minimally processed dietary pattern.
• Maintain healthy metabolic parameters.
• Avoid tobacco.
• Minimize or avoid alcohol.
• Optimize sleep.
• Address obesity, diabetes, hypertension and other cardiometabolic conditions.

Tier 2 — Higher recurrence risk

Discuss with the oncology team:

• more intensive surveillance where appropriate;
• tumor-specific biomarkers;
• ctDNA/MRD testing where clinically validated or appropriate;
• genomic and molecular risk assessment;
• body-composition monitoring;
• nutrition and exercise oncology;
• clinical trials;
• and evidence-based maintenance treatments specific to the cancer.

Tier 3 — Experimental metabolic strategies

For patients interested in repurposed drugs or nutraceutical combinations, the appropriate approach is research-informed shared decision-making.

Before adding an intervention, ask:

• What is the human clinical evidence?
• Is there randomized evidence?
• Is the proposed dose established for cancer?
• What are the known toxicities?
• Could it interact with current cancer therapy?
• Could it interfere with liver or kidney function?
• Could it affect blood counts?
• Could it alter drug metabolism?
• Is there a validated biomarker showing that the intervention is working?
• Could it delay or replace an evidence-based treatment?

15. Questions to Ask Your Oncology Team

1. What is my estimated recurrence risk?
2. What features of my original cancer make recurrence more or less likely?
3. What surveillance schedule is appropriate for me?
4. Which biomarkers are actually useful for my cancer?
5. Would ctDNA testing add meaningful information in my situation?
6. Should I undergo additional molecular or genomic testing?
7. What level of physical activity is appropriate for me?
8. Do I need nutritional assessment or a dietitian?
9. Am I losing muscle mass?
10. Do I have insulin resistance, diabetes or metabolic syndrome?
11. Are any of my current medications appropriate for both my conventional and metabolic health needs?
12. Are there relevant clinical trials of metabolic or repurposed therapies?
13. Could any supplement interfere with my cancer treatment?
14. What symptoms should trigger earlier reassessment?

16. Evidence Hierarchy for NED Maintenance

Intervention	Evidence Status	How to Position It
Cancer-specific surveillance	Established	Core of survivorship care
Physical activity	Strong survivorship evidence	Core lifestyle intervention
Healthy dietary pattern	Strong general-health evidence	Core lifestyle intervention
Muscle preservation	Strong clinical rationale	Core survivorship priority
ctDNA/MRD	Rapidly developing	Risk stratification; not automatically a treatment trigger
Vitamin D for deficiency	Established nutritional indication	Correct deficiency; do not assume anticancer benefit
Metformin	Cancer-specific evidence evolving	Use primarily for established medical indications or clinical trials
Statins / beta-blockers	Observational/mechanistic signals	Do not prescribe solely for cancer prevention without evidence
Mebendazole	Early clinical / investigational	Clinical-trial/research context preferred
Ivermectin	Preclinical + limited clinical evidence	Experimental; no established recurrence-prevention benefit
Fenbendazole	Insufficient clinical evidence	Research hypothesis, not established maintenance treatment
Curcumin / EGCG / quercetin / sulforaphane	Mechanistic and early clinical evidence varies	Adjunctive research; not proven recurrence prevention
Modified citrus pectin	Mechanistic / early evidence	Plausible adjunct; not proven to prevent recurrence

17. Conclusion: From "Waiting for Recurrence" to Intelligent Survivorship

Achieving NED should not be viewed as the end of the cancer journey.

But neither should it be viewed as proof that hidden cancer inevitably remains.

The most defensible approach is a layered one:

1. Detect: Maintain appropriate cancer-specific surveillance.

2. Stratify: Determine the patient's actual recurrence risk.

3. Monitor: Use validated biomarkers and imaging appropriately, with emerging tools such as ctDNA when clinically relevant.

4. Strengthen: Improve fitness, muscle mass, metabolic health, nutrition, sleep and cardiovascular health.

5. Personalize: Consider tumor biology, molecular characteristics and treatment history.

6. Investigate: Explore experimental metabolic and repurposed therapies primarily through clinical trials or carefully supervised shared decision-making.

The central idea is therefore not simply to "keep attacking cancer forever."

It is to build a long-term system in which cancer surveillance, metabolic health, physical resilience, immune health and precision medicine work together.

For some patients, this may mean little more than excellent survivorship care and healthy living. For others at substantially higher risk, it may justify more intensive monitoring and consideration of clinical trials or evidence-based maintenance therapy.

The future of cancer survivorship is unlikely to be a single universal protocol.

It is more likely to be adaptive, risk-stratified and increasingly personalized.

---

Medical and Evidence Disclaimer

This article is educational and does not constitute medical advice or a recommendation to self-treat cancer. NED does not guarantee cure, and recurrence risk varies substantially by cancer type, stage, molecular characteristics and treatment response.

Prescription medicines discussed in the context of cancer research may be off-label for oncology use. Veterinary medicines such as fenbendazole should not be substituted for approved human cancer treatments. Patients should not start, stop or alter prescription medicines or cancer treatment based on this article.

Experimental therapies should ideally be studied within appropriately designed clinical trials. Any use outside a clinical trial should involve an oncology professional who can assess potential benefits, toxicities, drug interactions and the possibility of interfering with established cancer treatment.

Selected Evidence and Further Reading

1. American Cancer Society. Nutrition and Physical Activity Guideline for Cancer Survivors.
2. Patel Y, et al. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? Current Oncology Reports. 2025.
3. Phan P, et al. Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors. Neuro-Oncology Practice. 2025.
4. Recent literature on ctDNA and minimal residual disease monitoring in solid tumors.
5. Current cancer-specific survivorship and surveillance guidelines should be consulted for individual patients.
6. Dr Paul Marik. After NED: Our Personalized Metabolic Trap Protocol to Keep High-Risk Cancer from Coming Back. 2026.
7. Dr Paul Marik. Maintenance Therapy After Achieving NED with a Multi-Axis Metabolic Approach. 2026.
8. Dr Paul Marik. The Evolution of Cancer Resistance: How Tumors Outsmart Therapy and Practical Strategies to Stay One Step Ahead. 2026.

Last reviewed: September 2026.